Weight Watchers Announces Best in Market Self-Pay Wegovy® Pricing for Med+ Members and the Launch of Preferred Subscription Pricing for Wegovy via NovoCare®

Weight Watchers (NASDAQ: WW) expanded collaboration with Novo Nordisk to offer Med+ members subscription pricing for Wegovy, promising the lowest available self-pay prices and up to $1,200 annual savings.

Rhea-AI Summary

Weight Watchers (NASDAQ: WW) expanded collaboration with Novo Nordisk to offer Med+ members subscription pricing for Wegovy, promising the lowest available self-pay prices and up to $1,200 annual savings.

Eligible members can pre-pay for 3, 6, or 12 months, with discounts on pens and pills and access to Wegovy across multiple doses.

Positive

• Up to $1,200 annual savings for eligible Med+ members
• Subscription pricing offers up to $100/month savings on Wegovy pens
• Subscription pricing offers up to $50/month savings on Wegovy pills
• 3, 6, or 12-month prepaid commitment options for members
• 29% greater weight loss when Weight Watchers lifestyle support is paired with GLP-1s

Negative

• None.

Argus Mar 31 session

+4.01% close to close Open Argus

Details

News Market Reaction – WW

In the Mar 31 session, WW gained 4.01%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement details an expansion of Weight Watchers’ collaboration with Novo Nordisk, giving M...

Analysis

This announcement details an expansion of Weight Watchers’ collaboration with Novo Nordisk, giving Med+ members access to best-in-market self-pay pricing on Wegovy and subscription options that can save up to $1,200 annually. It reinforces the company’s GLP‑1‑centric clinical strategy highlighted in recent earnings and GLP‑1 outcomes reports. Investors may watch how these pricing changes affect Med+ subscriber growth, clinical revenue mix, and member outcomes relative to prior metrics such as guidance of $620–$635 million in 2026 revenue.

Key Figures

Annual Wegovy savings: $1,200 per year Wegovy prepay terms: 3, 6, or 12 months Wegovy pill doses: 9 mg and 25 mg +5 more

Annual Wegovy savings

$1,200 per year

Maximum savings for eligible Med+ self-pay members

Wegovy prepay terms

3, 6, or 12 months

Pre-paid subscription commitment lengths for Wegovy

Wegovy pill doses

9 mg and 25 mg

Pill dose options included in subscription offer

Pen savings

$100 per month

Maximum monthly savings on Wegovy pens vs standard self-pay

Pill savings

$50 per month

Maximum monthly savings on Wegovy pills vs standard self-pay

Intro pill pricing

$149 per month

Starting-dose Wegovy pill price via limited-time offer

Weight loss uplift

29% greater

Weight loss vs drugs alone using Weight Watchers support system

GLP-1 savings scope

Best self-pay price

Described as lowest available self-pay Wegovy pricing for Med+ members

Historical Context

5 past events · Latest: Mar 16

5 events

1. Mar 16

   Earnings and guidance

   24h Move

   +4.6%

   Q4 and 2025 results beat guidance and 2026 outlook provided.

2. Mar 11

   GLP-1 outcomes report

   24h Move

   +1.2%

   Report showed Med+ GLP-1 program drives significantly greater weight loss.

3. Feb 27

   Earnings call scheduled

   24h Move

   +2.5%

   Announcement of timing for Q4 and full-year 2025 earnings call.

4. Feb 10

   Fitness partnership

   24h Move

   -2.1%

   PVOLVE partnership to add clinically validated strength workouts to programs.

5. Jan 07

   Investor conferences

   24h Move

   -1.2%

   Participation in January investor conferences and GLP‑1 positioning update.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

wegovy, glp-1, fda-approved, prescription, +4 more

8 terms

wegovy medical

"best in market self-pay Wegovy® pricing for Med+ members"

Wegovy is a prescription injectable medicine that mimics a naturally occurring hormone to reduce appetite and slow stomach emptying, helping people with obesity or overweight to lose and maintain weight. For investors, its importance lies in its large and growing demand, potential to shift healthcare costs and treatment patterns, and sensitivity to regulatory approvals, pricing, supply and competition—much like a blockbuster product that can reshape an industry’s revenue landscape.

glp-1 medical

"access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated care platform"

GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.

fda-approved regulatory

"increasing affordable access to FDA-approved GLP-1 treatment"

FDA-approved means a medical product, drug, device or treatment has passed the U.S. Food and Drug Administration’s review for safety and effectiveness for a specific use. Think of it like a formal safety and performance seal that allows the product to be marketed for that purpose in the U.S.; for investors, approval reduces regulatory uncertainty, enables sales and reimbursement pathways, and can materially affect a company’s revenue prospects and valuation.

prescription regulatory

"eligible Med+ members with a valid prescription can pre-pay for three, six, or 12 months"

A prescription is a formal authorization from a licensed healthcare professional that allows a patient to obtain and use a regulated medicine or treatment. For investors, prescriptions matter because they control who can buy certain drugs, drive sales volume and recurring revenue, and influence how quickly a new therapy is adopted—think of a prescription like a ticket that determines who gets access and how many tickets a company can sell.

subscription pricing financial

"access to subscription pricing for Wegovy® that significantly reduces out-of-pocket costs"

A pricing model where customers pay a regular, recurring fee (monthly, yearly, or other interval) for ongoing access to a product or service, similar to a gym or streaming membership. Investors care because subscription pricing creates predictable, repeatable revenue and lets companies show how fast they add and keep customers; small changes in price, sign-ups or cancellations can significantly affect future cash flow and valuation.

telehealth technical

"U.S. “Clinical” Med+ telehealth offering centered on GLP‑1 and related medications"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

deferred stock units financial

"an acquisition of derivative equity awards in the form of deferred stock units"

Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.

senior secured term loan financial

"a new $465.0 million senior secured term loan maturing in 2030"

A senior secured term loan is a type of borrowing where a company borrows money and promises to pay it back over a fixed period, with the loan secured by the company's assets as collateral. Because it is "senior," it has priority over other debts if the company faces financial trouble, and being "secured" means lenders have a claim on specific assets. For investors, this makes the loan a safer and more predictable investment compared to unsecured or subordinate debts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Through expanded collaboration with Novo Nordisk, eligible Med+ members can now save up to $1,200 per year on Wegovy®, increasing affordable access to FDA-approved GLP-1 treatment leveraging Weight Watchers’ integrated care platform

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that eligible Weight Watchers Med+ members will have access to subscription pricing for Wegovy® that significantly reduces out-of-pocket costs and is a result of expanded collaboration between Weight Watchers and Novo Nordisk.

The new subscription offer gives Weight Watchers Med+ members access to the lowest available self-pay price in the market for doses of Wegovy not otherwise available through limited-time offers, saving cash-pay members up to $1,200 per year. The announcement coincides with Novo Nordisk’s launch of the industry’s first-of-its-kind medication subscription pricing model for Wegovy and reinforces Weight Watchers’ role as a NovoCare® Recognized Care Provider and leader in integrated, evidence-based GLP-1 care.

“Novo Nordisk and Weight Watchers are each committed to helping those living with obesity take control of their health–and we are strengthening our collaboration to support that shared mission,” said Ed Cinca, Senior Vice President Marketing and Patient Solutions at Novo Nordisk. “We are making our subscription prices available to Med+ members to help them get and stay on treatment. This subscription option adds to ongoing efforts to meet people where they are, bringing transparency and predictability to those seeking treatment for obesity management.”

Through the new offer, eligible Med+ members with a valid prescription can pre-pay for three, six, or 12 months of Wegovy at a discounted monthly rate, including Wegovy pens across all doses and Wegovy pills at 9 mg and 25 mg doses. Depending on the commitment length, members can save up to $100 per month on pens and up to $50 per month on pills, versus the standard monthly self-pay price. Even without a multi-month commitment, members can take advantage of existing limited-time pricing offers, including starting doses of the Wegovy pill for only $149 per month. These offers give Med+ members best in market pricing for self-pay Wegovy.

“GLP-1s have helped millions across the world take control of their health -- but many more can't access these medications due to high costs.” said Scott Honken, Chief Commercial Officer of Weight Watchers. “That's why Weight Watchers is proud to introduce an expanded collaboration with Novo Nordisk, which gives our eligible Med+ members a more affordable and predictable path to access FDA-approved Wegovy. These reduced costs, combined with our unique lifestyle support system that drives 29% greater weight loss than the drugs alone, will continue to help Weight Watchers deliver the best GLP-1 results on the market.”

The expanded collaboration builds on Weight Watchers’ long-standing relationship with Novo Nordisk and reflects a shared commitment from both Weight Watchers and Novo Nordisk to improve access to FDA-approved weight health treatment.

Weight Watchers’ Med+ platform offers access to board-certified physicians, FDA-approved prescriptions, and lifestyle support to drive better outcomes and create lasting habits that can sustain results over time. Combined with the GLP-1 Success program, the Weight Watchers’ program helps members stay consistent with the tools they need for success throughout their GLP-1 journey.

The new medication commitment pricing offer comes as Weight Watchers’ clinical business grows rapidly, underscoring rising demand for its integrated GLP-1 model as more consumers seek a comprehensive approach to weight health.

As GLP-1 medications continue to reshape obesity care, Weight Watchers remains focused on what drives lasting results: pairing FDA-approved treatment with structured nutritional, behavioral, and lifestyle support. This expanded collaboration with Novo Nordisk marks another step in making that integrated model more affordable, accessible, and sustainable for the people who need it.

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For investor inquiries, please contact:
John Mills or Anna Kate Heller
WeightWatchers@icrinc.com

For media inquiries, please contact:
Lizzy Levitan
WW@hunt-gather.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What Wegovy subscription pricing did Weight Watchers (WW) announce on March 31, 2026?

Weight Watchers announced subscription pricing that can save eligible Med+ members up to $1,200 per year. According to Weight Watchers, members can pre-pay for 3, 6, or 12 months with discounted monthly rates on Wegovy pens and pills.

How much can Med+ members save per month on Wegovy pens and pills via WW (WW) subscription?

Med+ members can save up to $100/month on Wegovy pens and up to $50/month on Wegovy pills. According to Weight Watchers, savings vary by commitment length and dose selection.

Which Wegovy doses are included in the Weight Watchers (WW) NovoCare subscription offer announced March 31, 2026?

The offer covers Wegovy pens across all doses and Wegovy pills at 9 mg and 25 mg doses. According to Weight Watchers, eligible Med+ members with a valid prescription can access these doses via the subscription pricing.

Does the Weight Watchers (WW) program claim improved weight-loss outcomes when combined with Wegovy?

Weight Watchers reports its lifestyle support yields 29% greater weight loss versus drugs alone when paired with GLP-1 treatment. According to Weight Watchers, combining medication with structured support drives better sustained results.

Can Weight Watchers Med+ members access shorter-term Wegovy pricing without a multi-month commitment (WW)?

Yes. Members can use existing limited-time pricing, including starting doses of the Wegovy pill for $149 per month without a multi-month commitment. According to Weight Watchers, these offers remain available alongside subscription options.